Strategic Acquisition Merger and acquisition activity surrounding Harpoon Therapeutics indicates strong interest from major pharma players in immuno-oncology pipelines. Use this momentum to position supplemental deals, licensing of TriTAC platforms, or collaboration options around TriTAC-XR to mitigate safety concerns and accelerate development.

Pipeline Commercialization Harpoon’s TriTAC and ProTriTAC platforms target solid tumors and hematologic malignancies with a prodrug variant and an extended-release version. Explore co-development, regional licensing, or co-marketing arrangements to maximize reach of a differentiated T cell engager portfolio.

Clinical Leadership Recent executive hires and leadership changes, including Chief Legal Officer and Chief People Officer appointments, signal organizational maturation and governance readiness for more complex deals. Leverage this to propose structured partnership terms, robust IP protections, and clear compliance frameworks.

Financial Leverage Funding activity and reported revenue indicate a financially active and investor-backed company with scalable ambition. Propose milestone-based partnerships, upfronts tied to clinical milestones, and potential supply or manufacturing collaboration to scale production if commitments materialize.

Technology Differentiation Harpoon’s proprietary TriTAC, ProTriTAC, and XR platforms offer unique mechanisms to direct T cells and control cytokine release. Position opportunities for technology licensing, platform cross-licensing, or strategic collaborations to integrate with existing cell therapy pipelines or biomanufacturing capabilities.